AllSci News
China's SmartNuclide puts GPA33-directed pretargeted radioimmunotherapy into Phase I for CRC
A first-in-human trial of SNA028, a two-step pretargeted radioimmunotherapy targeting the GPA33 antigen, has been registered at Tianjin Medical University...
FDA accepts Viatris's NDA for MR-107A-02 fast-acting meloxicam for acute pain
Viatris (Nasdaq: VTRS) has submitted a New Drug Application (NDA) to the US FDA for MR-107A-02 (fast-acting meloxicam), an investigational oral...
CSPC's tissue factor-targeting ADC enters Phase I for advanced solid tumors
CSPC Pharmaceutical Group (HKEX: 1093) has initiated a first-in-human Phase I clinical trial of SYS6051, a tissue factor (TF)-targeting antibody-drug...
Cellio Therapeutics' iPSC-derived retinal pigment epithelium C.001 enters Phase I for RPE-mediated maculopathy
Cellio Therapeutics has opened a first-in-human Phase I trial of C.001, an autologous iPSC-derived retinal pigment epithelium cell therapy, in adults with...
Mestag's FAP-targeted lymphotoxin agonist aims to engineer tertiary lymphoid structures in cold tumors
Mestag Therapeutics, a Cambridge, UK-based clinical-stage biotech, has dosed the first patient in the STARLYS trial, a Phase I study evaluating MST-0312, a...
Relay Therapeutics' zovegalisib achieves 60% response rate in Phase II PIK3CA vascular anomalies trial
Relay Therapeutics (Nasdaq: RLAY) has reported initial zovegalisib clinical data from the Phase II ReInspire trial in PIK3CA-driven vascular anomalies,...
Japan approves Boehringer Ingelheim’s Jascayd for idiopathic and progressive pulmonary fibrosis
Boehringer Ingelheim’s Jascayd (nerandomilast) receives approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with idiopathic…
iECURE's ECUR-506 achieves 57% reduction in hyperammonemic events in OTC deficiency trial
iECURE reported statistically significant reductions in hyperammonemic events from the ECUR-506 OTC-HOPE trial, with the completed low-dose cohort showing a...
AeroRx posts positive Phase II data for nebulized LABA/LAMA drug in COPD
AeroRx Therapeutics has reported Phase 2a data for AERO-007, a nebulized fixed-dose combination of indacaterol and glycopyrrolate, showing statistically...
Enveric secures US patent for non-hallucinogenic psilocybin derivatives treating psychiatric disorders
Enveric Biosciences (Nasdaq: ENVB), headquartered in Cambridge, Massachusetts, announced receipt of US Patent No. 12,605,361 from the USPTO on April 21, 2026,…
Bayer’s asundexian Factor XIa inhibitor receives FDA Priority Review for secondary stroke prevention
Bayer (XETRA: BAYN) announced that the US FDA has accepted its New Drug Application (NDA) and granted Priority Review designation for asundexian…
Gossamer Bio exchanges USD 120m convertible debt to stabilize balance sheet ahead of seralutinib PAH filing
San Diego-based Gossamer Bio (Nasdaq: GOSS) has announced an exchange offer and concurrent consent solicitation targeting more than USD 120 million of its...
Hansa Biopharma licenses Europe, MENA rights for Idefirix to SERB Pharmaceuticals for EUR 115m
Hansa Biopharma (Nasdaq Stockholm: HNSA), the Lund, Sweden-based biopharmaceutical company, has licensed European and MENA commercialization rights for...
ImmunityBio secures five US patents for ANKTIVA plus BCG bladder cancer therapy through 2035
ImmunityBio (Nasdaq: IBRX), headquartered in Culver City, California, has received five issued US patents covering the combination of its IL-15 receptor agonist…
Nanobiotix's JNJ-1900 produces strong early Phase II data in stage III lung cancer
Nanobiotix (Euronext: NANO; Nasdaq: NBTX) reported an 85.7% overall response rate and a 57.1% complete response rate in seven patients with stage III...
The AllSci Brief
Systematic R&D and deal news. Daily.